Affordable Medicines Europe

What Affordable Medicines Europe does

Affordable Medicines Europe is a Brussels-based trade association founded in June 1998 that represents licensed independent pharmaceutical distributors engaged in the parallel import and export of medicines across the European Economic Area. The association is governed by a Board of Directors, working groups (legal, regulatory, advocacy, Falsified Medicines Directive), and a twice-yearly General Assembly, and it operates with a small secretariat of five staff. Its members — 18 national associations and 120+ individual companies in 20 EU/EEA member states plus the UK — hold Good Distribution Practices (GDP) licenses and, where they import, Good Manufacturing Practices (GMP) licenses; they collectively represent approximately 85% of Europe's parallel import market volume, an industry that generated €7.67 billion in annual sales in 2024 and is reported to save European healthcare payers and patients €5-7 billion per year.

The association's core services to members include GDP audit scheme certification under its own Good Parallel Distribution Guidelines, an anti-counterfeit warning platform, and access to the European Medicines Verification System (EMVS) through its founding-membership stake in the European Medicines Verification Organisation (EMVO), co-founded in 2015 alongside EFPIA, GIRP, Medicines for Europe, and PGEU. Its revenue model is a recurring membership-subscription model funded by national associations and corporate members, with fees set by the General Assembly and not publicly disclosed. Public-facing activity combines policy advocacy (position papers on shortages, transparency directive revision, supply-chain diversification) with a digital awareness campaign (#FillTheGap) and rotating General Assemblies in different European cities, the most recent scheduled for Vilnius in May 2026.

Name

Affordable Medicines Europe

Legal name

Affordable Medicines Europe

Website

https://affordablemedicines.eu

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

Brussels-based trade association founded in 1998 representing 120+ licensed independent pharmaceutical distributors across 20 EU/EEA states and the UK, collectively handling ~85% of Europe's parallel import market volume through GDP/GMP-certified operations.

Ownership category

akta.pro rank

Product category

Pharmaceutical Trade Association

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

Keywords

• Parallel import medicines
• Pharmaceutical distribution association
• Medicine shortage mitigation
• GDP audit certification
• Pharmaceutical trade advocacy

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Membership dues: Association funded through membership fees from 18 national associations and individual company members across 20 EU/EEA countries and the UK. Membership provides access to working groups, General Assembly meetings, GDP audit scheme, anti-counterfeit warning platform, and cooperation with supply chain stakeholders.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Affordable Medicines Europe is a Brussels-based trade association representing licensed pharmaceutical independent distributors engaged in parallel import and export of medicines across the EU/EEA. Its core offering is association membership that includes working group participation, General Assembly meetings, a GDP audit scheme, anti-counterfeit warning platform, and access to the European Medicines Verification System, supporting price competition, medicine shortage mitigation, and safety of parallel-distributed medicines.

Product overview

Affordable Medicines Europe is an association representing licensed independent distributors of medicines across Europe, not a product company. The association operates as a membership organization offering participation in working groups (legal, regulatory, advocacy, Falsified Medicines Directive), GDP audit certification, anti-counterfeit warning platforms, and access to the European Medicines Verification System. Through 18 national associations and individual companies in 20 EU/EEA member states and the UK, members gain networking opportunities, knowledge sharing, and participation in the association's audit scheme. The association facilitates parallel trade of medicines to mitigate shortages and create savings for healthcare systems.

Differentiator

Problem solved

Functional benefit

Products and services

• Affordable Medicines Europe Association Membership Membership program exclusively for companies holding a wholesale license (Good Distribution Practices), providing access to working groups, General Assembly meetings, GDP audit scheme certification, anti-counterfeit warning platform, and cooperation with supply chain stakeholders.
• GDP Audit Scheme and Certification Internal audit scheme operated by Affordable Medicines Europe that certifies members' compliance with Good Distribution Practices (GDP) and the association's Good Parallel Distribution Guidelines code of conduct.
• Anti-Counterfeit Warning Platform Platform operated by Affordable Medicines Europe enabling members to share warnings about counterfeit or falsified pharmaceutical products circulating in Europe.
• European Medicines Verification System (EMVS) Access Member access to the European Medicines Verification Organization's system for verifying medicines through unique identifiers and anti-tampering devices as required by the Falsified Medicines Directive.
• Knowledge Sharing and Networking Platform Platform facilitating knowledge sharing and networking among members, including working groups on legal, regulatory, advocacy, and Falsified Medicines Directive topics, and cooperation with other supply chain stakeholders.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• European Medicines Verification Organisation (EMVO)coreStrategic or Co-development Partner · 1 January 2015Affordable Medicines Europe is one of five founding members of EMVO, established to ensure the functioning of the European Medicines Verification System (EMVS). The EMVS ensures supply chains of medicines are free from falsified medicines through end-to-end verification. Other founders include EFPIA (industry), GIRP (wholesalers), Medicines for Europe, and PGEU (pharmacists).

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Medicines for Europe: European trade association for generics, biosimilars, and value-added medicines. Both operate as Brussels-based pharma trade associations engaging in EU regulatory advocacy, and Medicines for Europe is a sibling organization with overlap in policy interests, EMVO co-founding, and member base.
• GIRP (European Healthcare Distribution Association): Represents full-line pharmaceutical wholesalers and healthcare distributors in Europe. GIRP covers the broader wholesale channel while Affordable Medicines Europe focuses on parallel distribution, but both engage EU regulators on GDP licensing, supply chain resilience, and Falsified Medicines Directive implementation, and are co-founders of EMVO.
• PGEU (Pharmaceutical Group of the European Union): Represents community pharmacists across Europe. PGEU interfaces with parallel distributors at the dispensing end of the supply chain and is the fifth co-founder of EMVO, making it a directly comparable Brussels-based pharma stakeholder association.

Broad incumbents

• EFPIA (European Federation of Pharmaceutical Industries and Associations): Largest European pharma industry association representing originator manufacturers. EFPIA operates on the opposite side of the parallel-trade debate, but is structurally comparable as a Brussels-based pharma advocacy organization and a fellow EMVO founder.

Regional players

• LEEM (Les Entreprises du Médicament): French pharma industry association representing originator and generic companies in France. Comparable institutional analogue at the national level for a major parallel-import destination market, even though its stance on parallel trade differs from Affordable Medicines Europe's.
• BAH (Bundesverband der Arzneimittel-Hersteller): German pharma industry association representing both manufacturers and distributors in Germany. BAH is the dominant national-association counterpart on the largest single market in which parallel trade is active, where Affordable Medicines Europe has the largest concentration of member companies.

Others

• European Medicines Verification Organisation (EMVO): EMVO is not a competitor but a closely linked ecosystem organization co-founded by Affordable Medicines Europe in 2015. Its governance and operations directly intersect with the association's mandate on Falsified Medicines Directive implementation.
• EuropaBio: European association for the biotechnology industry, including industrial and healthcare biotech. A comparable Brussels-based life-sciences advocacy body working on parallel EU policy files (pricing, market access, supply security).
• AESGP (Association of the European Self-Care Industry): European trade association for self-care, OTC, and consumer health product manufacturers. Operates in adjacent regulatory space (medicines categorization, advertising, supply chain) and engages the same EU policy stakeholders as Affordable Medicines Europe.
• EUCOPE (European Confederation of Pharmaceutical Entrepreneurs): European association representing small and mid-sized innovative pharma companies. Operates adjacent to Affordable Medicines Europe in EU policy advocacy on pharmaceutical regulation, market access, and supply security, sharing similar Brussels-based association infrastructure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/affordable-medicines-europe
• Xx.com/AffordableMedEU

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Affordable Medicines Europe